Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review

Correction: Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review

Bibliographic Details
Main Authors:	Nikki Bozinoff, Vitor Soares Tardelli, Dafna Sara Rubin-Kahana, Bernard Le Foll
Format:	Article
Language:	English
Published:	BMC 2022-11-01
Series:	Harm Reduction Journal
Online Access:	https://doi.org/10.1186/s12954-022-00705-6

Similar Items

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review
by: Nikki Bozinoff, et al.
Published: (2022-10-01)

The impact of cannabis legalization for recreational purposes on youth: A narrative review of the Canadian experience
by: Dafna Sara Rubin-Kahana, et al.
Published: (2022-09-01)

Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample
by: Dafna Sara Rubin-Kahana, et al.
Published: (2022-04-01)

Multiple Substance Use Disorders and Self-Reported Cognitive Function in U.S. Adults: Associations and Sex-Differences in a Nationally Representative Sample
by: Zoe Bourgault, et al.
Published: (2022-01-01)

The Insula: A Brain Stimulation Target for the Treatment of Addiction
by: Christine Ibrahim, et al.
Published: (2019-07-01)

Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France
by: Salim Mezaache, et al.
Published: (2021-01-01)

Correction to: Individual and structural correlates of willingness for intravenous buprenorphine treatment among people who inject sublingual buprenorphine in France
by: Salim Mezaache, et al.
Published: (2021-02-01)

Neurochemical Alterations in Social Anxiety Disorder (SAD): A Systematic Review of Proton Magnetic Resonance Spectroscopic Studies
by: Sonja Elsaid, et al.
Published: (2022-04-01)

Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco
by: Jamie Carter, et al.
Published: (2019-05-01)

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
by: Bruce, R.D., et al.
Published: (2009)

Pharmacokinetics of buprenorphine in pregnant sheep after intravenous injection
by: Henriikka Hakomäki, et al.
Published: (2021-04-01)

Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia
by: Vijay, A., et al.
Published: (2015)

Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.
by: Régis Bouquié, et al.
Published: (2014-01-01)

Buprenorphine
by: Jaroslaw Mazurek, et al.
Published: (2014-06-01)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
by: H. Elarabi, et al.
Published: (2022-06-01)

Unusual Route of Buprenorphine Administration: An Alternative Approach for Bypassing Adverse Drug Reactions
by: Azadeh Nazari, MD, Ph.D., et al.
Published: (2019-01-01)

Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
by: Van Thi Thanh Truong, et al.
Published: (2023-04-01)

“Not doing it justice”: Perspectives of Recent Family Medicine Graduates on Mental Health and Addictions Training in Residency
by: Abigail Ramdawar, et al.
Published: (2024-04-01)

Impacts of recreational cannabis legalization on use and harms: A narrative review of sex/gender differences
by: Justin Matheson, et al.
Published: (2023-03-01)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
by: Hassan Ziaaddini, et al.
Published: (2018-12-01)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
by: Ling W, et al.
Published: (2019-11-01)

Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk
by: Frances R Levin, et al.
Published: (2023-10-01)

Transition from First Drug Use to Regular Injection among People Who Inject Drugs in Iran
by: Masoomeh Koozegar, et al.
Published: (2018-08-01)

Cannabis Legalization and Acute Harm From High Potency Cannabis Products: A Narrative Review and Recommendations for Public Health
by: Justin Matheson, et al.
Published: (2020-09-01)

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study
by: Edward Suarez, et al.
Published: (2023-12-01)

A Multistage Process Model of How a Person Who Currently Injects Drugs Comes to Assist Persons Who Do not Inject with Their First Injections
by: Don C. Des Jarlais, et al.
Published: (2021-02-01)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
by: Ling W, et al.
Published: (2020-01-01)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01)

WHO efforts to promote reporting of adverse events and global learning
by: Itziar Larizgoitia, et al.
Published: (2013-12-01)

Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs
by: Travis M. Scott, et al.
Published: (2021-10-01)

Healthcare staff’s perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
by: Johan Nordgren, et al.
Published: (2024-04-01)

Transcriptomic Characterization of the Human Habenula Highlights Drug Metabolism and the Neuroimmune System
by: Bernard Le Foll, et al.
Published: (2018-10-01)

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events
by: Christopher J Cates, et al.

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
by: Bestepe EE, et al.
Published: (2020-11-01)

Is thrombotic event a side effect of oral buprenorphine abuse? Two case reports
by: Toktam Alirezaei, et al.
Published: (2019-04-01)

“We want everything in a one-stop shop”: acceptability and feasibility of PrEP and buprenorphine implementation with mobile syringe services for Black people who inject drugs
by: Tyler S. Bartholomew, et al.
Published: (2022-12-01)

Transcriptomic Characterization of the Human Insular Cortex and Claustrum
by: Christine Ibrahim, et al.
Published: (2019-11-01)

Buprenorphine: Far Beyond the “Ceiling”
by: Rosmara Infantino, et al.
Published: (2021-05-01)

Influence of buprenorphine replacement therapy
by: Despotović Milena, et al.
Published: (2017-01-01)

Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats
by: Venumadhav Janganati, et al.
Published: (2023-05-01)